🚀 VC round data is live in beta, check it out!
ArriVent BioPharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for ArriVent BioPharma and similar public comparables like CureVac, Kaken Pharmaceutical, Mega Lifesciences, AprilBio and more.
ArriVent BioPharma Overview
About ArriVent BioPharma
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team’s deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Founded
2021
HQ
Employees
52
Website
Sectors
Financials (LTM)
EV
$744M
ArriVent BioPharma Financials
ArriVent BioPharma reported last 12-month revenue of — and negative EBITDA of ($178M).
In the same LTM period, ArriVent BioPharma generated — in gross profit, ($178M) in EBITDA losses, and had net loss of ($167M).
Revenue (LTM)
ArriVent BioPharma P&L
In the most recent fiscal year, ArriVent BioPharma reported revenue of — and EBITDA of ($178M).
ArriVent BioPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($178M) | XXX | ($178M) | XXX | XXX | XXX |
| Net Profit | ($167M) | XXX | ($166M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ArriVent BioPharma Stock Performance
ArriVent BioPharma has current market cap of $1B, and enterprise value of $744M.
Market Cap Evolution
ArriVent BioPharma's stock price is $25.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $744M | $1B | 0.0% | XXX | XXX | XXX | $-4.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArriVent BioPharma Valuation Multiples
ArriVent BioPharma trades at (4.2x) EV/EBITDA.
EV / Revenue (LTM)
ArriVent BioPharma Financial Valuation Multiples
As of March 21, 2026, ArriVent BioPharma has market cap of $1B and EV of $744M.
Equity research analysts estimate ArriVent BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ArriVent BioPharma has a P/E ratio of (6.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $744M | XXX | $744M | XXX | XXX | XXX |
| EV/EBITDA | (4.2x) | XXX | (4.2x) | XXX | XXX | XXX |
| EV/EBIT | (4.2x) | XXX | (4.2x) | XXX | XXX | XXX |
| P/E | (6.3x) | XXX | (6.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ArriVent BioPharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ArriVent BioPharma Margins & Growth Rates
ArriVent BioPharma's revenue in the last fiscal year grew by —.
ArriVent BioPharma's revenue per employee in the last FY averaged $0.0M.
ArriVent BioPharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | (0%) | XXX | 2% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ArriVent BioPharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| CureVac | XXX | XXX | XXX | XXX | XXX | XXX |
| Kaken Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| AprilBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ArriVent BioPharma M&A Activity
ArriVent BioPharma acquired XXX companies to date.
Last acquisition by ArriVent BioPharma was on XXXXXXXX, XXXXX. ArriVent BioPharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ArriVent BioPharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialArriVent BioPharma Investment Activity
ArriVent BioPharma invested in XXX companies to date.
ArriVent BioPharma made its latest investment on XXXXXXXX, XXXXX. ArriVent BioPharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ArriVent BioPharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ArriVent BioPharma
| When was ArriVent BioPharma founded? | ArriVent BioPharma was founded in 2021. |
| Where is ArriVent BioPharma headquartered? | ArriVent BioPharma is headquartered in United States. |
| How many employees does ArriVent BioPharma have? | As of today, ArriVent BioPharma has over 52 employees. |
| Who is the CEO of ArriVent BioPharma? | ArriVent BioPharma's CEO is Zhengbin Yao. |
| Is ArriVent BioPharma publicly listed? | Yes, ArriVent BioPharma is a public company listed on Nasdaq. |
| What is the stock symbol of ArriVent BioPharma? | ArriVent BioPharma trades under AVBP ticker. |
| When did ArriVent BioPharma go public? | ArriVent BioPharma went public in 2024. |
| Who are competitors of ArriVent BioPharma? | ArriVent BioPharma main competitors are CureVac, Kaken Pharmaceutical, Mega Lifesciences, AprilBio. |
| What is the current market cap of ArriVent BioPharma? | ArriVent BioPharma's current market cap is $1B. |
| Is ArriVent BioPharma profitable? | No, ArriVent BioPharma is not profitable. |
| What is the current EBITDA of ArriVent BioPharma? | ArriVent BioPharma has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of ArriVent BioPharma? | Current EBITDA multiple of ArriVent BioPharma is (4.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.